In this issue:
Risankizumab efficacious for active PsA
Comorbidities in patients with PsA linked to increased mortality
Gut dysbiosis associated with worse disease activity and physical function in axSpA
Tofacitinib elicits rapid improvements across a range of outcome measures
Do tender joints in PsA reflect imaging-assessed inflammation?
Pfizer COVID vaccine immunogenetic in PsA patients on TNF inhibitors
Classification of axSpA as radiographic or non-radiographic doesn’t aid prognostication
Low prevalence of MRI-defined axSpA in PsA
Secukinumab provides long-term NSAID-sparing effects
X-ray vs MRI for diagnosing axSpA
Please login below to download this issue (PDF)